Histograms showing mean and standard error demonstrating the association of intratumoral LAG-3 expression and LMP1/2-specific CD8⁺ T-cell responses in ND/RL HL patients prior to therapy. ELISPOT responses were compared in patients categorized as either low (0% to 25%) or high (26% to 100%) LAG-3–expressing tumor-infiltrating lymphocytes within HL lymph nodes.